Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer

N. Hanna*, P. Ohana, F. M. Konikoff, G. Leichtmann, A. Hubert, L. Appelbaum, Y. Kopelman, A. Czerniak, A. Hochberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences